^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Atezolizumab (Tecentriq®) is accepted for use within NHSScotland
Published date:
10/09/2020
Excerpt:
Atezolizumab, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Secondary therapy:
carboplatin + etoposide IV
Source:
Excerpt:
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Secondary therapy:
carboplatin + etoposide IV
Source:
Title:
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
04/14/2021
Excerpt:
Recommendations: An anti-PD-L1 inhibitor (atezolizumab [I, A; ESMO-MCBS v1.1 score: 3] or durvalumab [I, A; ESMO-MCBS v1.1 score: 3]) in combination with four to six cycles of a platinum and etoposide can be offered to all patients with treatment-naive extensive-stage SCLC, a PS of 0-1 and no contraindications for immunotherapy [I, A].
Secondary therapy:
etoposide IV
DOI:
10.1016/j.annonc.2021.03.207
Source:
Excerpt:
The NCCN SCLC Panel recommends (category 1) carboplatin plus etoposide plus atezolizumab as a preferred first-line systemic therapy option followed by maintenance atezolizumab for patients with extensive-stage SCLC...
Secondary therapy:
carboplatin + etoposide IV
